Pfizer Surges on Strong Q1 Earnings, Beats Estimates

Pfizer commenced 2026 with a robust first quarter, surpassing expectations and driving its stock higher. The company announced adjusted earnings of $0.75 per share, exceeding the $0.72 consensus, with total revenue reaching $13.8 billion. A notable 22% increase in operational revenue from new and recently acquired therapies highlights Pfizer's strategic growth.

Despite a 9% year-over-year decrease in net income to $2.7 billion, Pfizer reiterated its 2026 financial projections. Management anticipates adjusted earnings per share between $2.80 and $3.00, with total revenue forecasted at $59.5 billion to $62.5 billion. The company also confirmed no share repurchases are planned for 2026.

CEO Albert Bourla expressed optimism, citing positive trial outcomes and advancing research in oncology and weight management. While the company faces the challenge of upcoming patent cliffs for key medications like Eliquis before 2030, it is actively mitigating this through strategic acquisitions, pipeline development, and agreements with generic producers for therapies such as Vyndaqel.